Noble Financial Sticks to Its Buy Rating for TherapeuticsMD (TXMD)

By Carrie Williams

Noble Financial analyst Ahu Demir maintained a Buy rating on TherapeuticsMD (TXMDResearch Report) yesterday. The company’s shares closed last Monday at $3.78.

According to, Demir is a 3-star analyst with an average return of 5.8% and a 39.1% success rate. Demir covers the Healthcare sector, focusing on stocks such as Onconova Therapeutics, Dyadic International, and Electrocore Llc.

TherapeuticsMD has an analyst consensus of Strong Buy, with a price target consensus of $8.33, a 98.3% upside from current levels. In a report issued on September 25, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $13.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.60 and a one-year low of $1.82. Currently, TherapeuticsMD has an average volume of 3.18M.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TXMD in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes.